 Peter Mourani
Concepts (458)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 23 | 2021 | 330 | 5.110 |
Why?
| | Intensive Care Units, Pediatric | 26 | 2023 | 147 | 2.940 |
Why?
| | Cardiopulmonary Resuscitation | 14 | 2023 | 220 | 2.450 |
Why?
| | Heart Arrest | 15 | 2023 | 289 | 2.410 |
Why?
| | Respiration, Artificial | 17 | 2023 | 525 | 2.190 |
Why?
| | Critical Illness | 23 | 2024 | 646 | 2.110 |
Why?
| | Infant, Premature | 17 | 2021 | 477 | 2.080 |
Why?
| | Hypertension, Pulmonary | 13 | 2023 | 1751 | 2.060 |
Why?
| | Pneumonia, Ventilator-Associated | 3 | 2021 | 41 | 1.970 |
Why?
| | Microbiota | 8 | 2024 | 651 | 1.890 |
Why?
| | Shock, Septic | 11 | 2023 | 184 | 1.840 |
Why?
| | Sepsis | 12 | 2023 | 519 | 1.500 |
Why?
| | Child | 86 | 2024 | 18550 | 1.370 |
Why?
| | Trachea | 3 | 2017 | 234 | 1.370 |
Why?
| | Respiratory Insufficiency | 5 | 2021 | 292 | 1.370 |
Why?
| | Prospective Studies | 42 | 2024 | 6266 | 1.360 |
Why?
| | Respiratory Tract Infections | 5 | 2024 | 323 | 1.320 |
Why?
| | Infant, Newborn | 40 | 2024 | 5089 | 1.320 |
Why?
| | Vascular Diseases | 5 | 2020 | 230 | 1.140 |
Why?
| | Critical Care | 6 | 2021 | 476 | 1.070 |
Why?
| | Premature Birth | 4 | 2021 | 278 | 1.050 |
Why?
| | Infant | 42 | 2024 | 8002 | 0.970 |
Why?
| | Echocardiography | 7 | 2021 | 566 | 0.940 |
Why?
| | Lung | 9 | 2024 | 3684 | 0.920 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2022 | 224 | 0.910 |
Why?
| | Influenza, Human | 9 | 2023 | 549 | 0.890 |
Why?
| | Humans | 125 | 2024 | 115888 | 0.890 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 32 | 0.880 |
Why?
| | Child, Preschool | 35 | 2024 | 9174 | 0.880 |
Why?
| | Heart Ventricles | 2 | 2021 | 712 | 0.880 |
Why?
| | Intensive Care Units | 9 | 2023 | 616 | 0.860 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2021 | 492 | 0.810 |
Why?
| | Ventricular Function, Right | 2 | 2021 | 251 | 0.790 |
Why?
| | Intubation, Intratracheal | 3 | 2019 | 215 | 0.790 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2019 | 97 | 0.780 |
Why?
| | Quality of Life | 12 | 2024 | 2391 | 0.740 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 221 | 0.710 |
Why?
| | Patient Discharge | 11 | 2024 | 770 | 0.680 |
Why?
| | Aftercare | 5 | 2024 | 187 | 0.650 |
Why?
| | Male | 55 | 2024 | 56121 | 0.610 |
Why?
| | Nutritional Support | 1 | 2017 | 27 | 0.610 |
Why?
| | Echocardiography, Doppler | 3 | 2018 | 90 | 0.600 |
Why?
| | Respiratory Tract Diseases | 1 | 2019 | 142 | 0.600 |
Why?
| | Female | 58 | 2024 | 60075 | 0.590 |
Why?
| | Gestational Age | 7 | 2021 | 757 | 0.590 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 97 | 0.580 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2013 | 47 | 0.550 |
Why?
| | Risk Factors | 20 | 2022 | 8714 | 0.540 |
Why?
| | Coinfection | 3 | 2022 | 120 | 0.540 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 2015 | 9 | 0.510 |
Why?
| | Adolescent | 34 | 2023 | 17949 | 0.500 |
Why?
| | Energy Intake | 1 | 2017 | 413 | 0.500 |
Why?
| | Nitric Oxide | 6 | 2022 | 834 | 0.490 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2014 | 15 | 0.470 |
Why?
| | Chlorides | 3 | 2020 | 130 | 0.470 |
Why?
| | Paramyxoviridae Infections | 1 | 2013 | 10 | 0.470 |
Why?
| | Metapneumovirus | 1 | 2013 | 12 | 0.460 |
Why?
| | Retrospective Studies | 26 | 2023 | 12615 | 0.460 |
Why?
| | Myocardial Contraction | 1 | 2015 | 316 | 0.450 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 99 | 0.450 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 130 | 0.450 |
Why?
| | Bacteria | 4 | 2022 | 731 | 0.440 |
Why?
| | Energy Metabolism | 1 | 2017 | 712 | 0.430 |
Why?
| | Brain Injuries, Traumatic | 3 | 2023 | 302 | 0.420 |
Why?
| | Patient Readmission | 2 | 2018 | 607 | 0.420 |
Why?
| | Pulmonary Embolism | 2 | 2012 | 182 | 0.420 |
Why?
| | Peripheral Vascular Diseases | 1 | 2013 | 98 | 0.420 |
Why?
| | Lung Diseases | 2 | 2010 | 710 | 0.410 |
Why?
| | Oxygen | 3 | 2019 | 839 | 0.410 |
Why?
| | Bacterial Infections | 3 | 2023 | 222 | 0.410 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 468 | 0.400 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 234 | 0.400 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 3 | 0.390 |
Why?
| | Embolectomy | 1 | 2011 | 10 | 0.390 |
Why?
| | Bereavement | 2 | 2021 | 51 | 0.380 |
Why?
| | Acute Kidney Injury | 4 | 2021 | 647 | 0.370 |
Why?
| | Influenza A virus | 3 | 2020 | 91 | 0.370 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 363 | 0.370 |
Why?
| | Wilms Tumor | 1 | 2011 | 66 | 0.360 |
Why?
| | Pulmonary Artery | 3 | 2011 | 1032 | 0.360 |
Why?
| | Milrinone | 2 | 2021 | 25 | 0.360 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1403 | 0.350 |
Why?
| | Vasodilator Agents | 3 | 2021 | 308 | 0.350 |
Why?
| | Water-Electrolyte Imbalance | 2 | 2020 | 26 | 0.330 |
Why?
| | Coronary Care Units | 2 | 2018 | 13 | 0.320 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 193 | 0.320 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2008 | 82 | 0.310 |
Why?
| | Infant, Extremely Premature | 2 | 2020 | 58 | 0.310 |
Why?
| | Sulfones | 1 | 2008 | 98 | 0.310 |
Why?
| | Multiple Organ Failure | 3 | 2023 | 144 | 0.300 |
Why?
| | Hernia, Diaphragmatic | 1 | 2008 | 66 | 0.300 |
Why?
| | Logistic Models | 6 | 2019 | 1865 | 0.300 |
Why?
| | Quality Improvement | 3 | 2022 | 956 | 0.300 |
Why?
| | Cohort Studies | 13 | 2022 | 4961 | 0.300 |
Why?
| | Heart Diseases | 2 | 2023 | 337 | 0.290 |
Why?
| | Administration, Inhalation | 5 | 2022 | 647 | 0.290 |
Why?
| | Health Resources | 4 | 2022 | 122 | 0.290 |
Why?
| | Kidney Neoplasms | 1 | 2011 | 325 | 0.290 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 243 | 0.290 |
Why?
| | Staphylococcus | 2 | 2017 | 69 | 0.290 |
Why?
| | Research Design | 4 | 2022 | 947 | 0.280 |
Why?
| | Staphylococcal Infections | 2 | 2022 | 338 | 0.280 |
Why?
| | Metagenomics | 4 | 2023 | 132 | 0.270 |
Why?
| | Piperazines | 1 | 2008 | 313 | 0.270 |
Why?
| | Follow-Up Studies | 8 | 2021 | 4446 | 0.270 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2008 | 187 | 0.270 |
Why?
| | Hospital Mortality | 8 | 2023 | 784 | 0.260 |
Why?
| | Length of Stay | 4 | 2020 | 963 | 0.260 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 1486 | 0.250 |
Why?
| | Biomarkers | 8 | 2023 | 3473 | 0.250 |
Why?
| | Pregnancy | 9 | 2022 | 5555 | 0.240 |
Why?
| | Time Factors | 9 | 2020 | 6186 | 0.240 |
Why?
| | Diastole | 3 | 2019 | 135 | 0.240 |
Why?
| | Ribosomal Protein S6 | 1 | 2004 | 15 | 0.240 |
Why?
| | DEAD Box Protein 58 | 2 | 2022 | 8 | 0.230 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 37 | 0.230 |
Why?
| | Tunica Intima | 1 | 2004 | 78 | 0.230 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2004 | 418 | 0.230 |
Why?
| | Skin Pigmentation | 1 | 2024 | 40 | 0.230 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2437 | 0.230 |
Why?
| | Oximetry | 1 | 2024 | 80 | 0.220 |
Why?
| | Epinephrine | 2 | 2022 | 166 | 0.220 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 147 | 0.220 |
Why?
| | Respiration | 1 | 2024 | 180 | 0.220 |
Why?
| | Age Factors | 6 | 2021 | 2915 | 0.210 |
Why?
| | Treatment Outcome | 11 | 2022 | 9165 | 0.210 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2022 | 13 | 0.210 |
Why?
| | Receptors, Immunologic | 2 | 2022 | 201 | 0.210 |
Why?
| | Cotinine | 1 | 2023 | 69 | 0.210 |
Why?
| | Wounds and Injuries | 2 | 2021 | 731 | 0.210 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2022 | 11 | 0.210 |
Why?
| | Hypotension | 1 | 2023 | 116 | 0.200 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2004 | 235 | 0.200 |
Why?
| | Sodium | 1 | 2022 | 182 | 0.200 |
Why?
| | Protein Kinases | 1 | 2004 | 306 | 0.200 |
Why?
| | Glasgow Coma Scale | 4 | 2023 | 144 | 0.200 |
Why?
| | Central Venous Catheters | 1 | 2022 | 40 | 0.200 |
Why?
| | Smoke | 1 | 2023 | 133 | 0.200 |
Why?
| | Parents | 4 | 2021 | 1210 | 0.190 |
Why?
| | Central Venous Pressure | 1 | 2021 | 12 | 0.190 |
Why?
| | Prone Position | 1 | 2021 | 27 | 0.190 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2022 | 60 | 0.190 |
Why?
| | United States | 11 | 2022 | 12339 | 0.190 |
Why?
| | Capnography | 1 | 2021 | 11 | 0.190 |
Why?
| | Shock | 1 | 2022 | 75 | 0.190 |
Why?
| | Patient Positioning | 1 | 2021 | 43 | 0.190 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1090 | 0.190 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2022 | 121 | 0.190 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2021 | 41 | 0.190 |
Why?
| | Pregnancy in Diabetics | 1 | 2022 | 82 | 0.190 |
Why?
| | Common Data Elements | 1 | 2020 | 10 | 0.190 |
Why?
| | ADAMTS4 Protein | 1 | 2020 | 16 | 0.190 |
Why?
| | Thoracic Injuries | 1 | 2021 | 54 | 0.190 |
Why?
| | Communicable Diseases | 1 | 2022 | 131 | 0.190 |
Why?
| | Iloprost | 1 | 2021 | 46 | 0.190 |
Why?
| | Catheterization, Central Venous | 1 | 2022 | 89 | 0.190 |
Why?
| | Spinal Injuries | 1 | 2021 | 48 | 0.190 |
Why?
| | Multiple Trauma | 1 | 2021 | 91 | 0.190 |
Why?
| | Vasopressins | 1 | 2021 | 57 | 0.180 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2021 | 319 | 0.180 |
Why?
| | Young Adult | 9 | 2022 | 10515 | 0.180 |
Why?
| | Extremities | 1 | 2021 | 113 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 2 | 2023 | 3086 | 0.180 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 71 | 0.180 |
Why?
| | Abdominal Injuries | 1 | 2021 | 98 | 0.180 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 609 | 0.180 |
Why?
| | Epoprostenol | 1 | 2021 | 132 | 0.180 |
Why?
| | Angiogenic Proteins | 1 | 2020 | 18 | 0.180 |
Why?
| | Radiography, Thoracic | 1 | 2021 | 165 | 0.180 |
Why?
| | Morbidity | 4 | 2022 | 280 | 0.170 |
Why?
| | Caregivers | 3 | 2021 | 714 | 0.170 |
Why?
| | Multivariate Analysis | 4 | 2018 | 1444 | 0.170 |
Why?
| | Medical Audit | 1 | 2020 | 76 | 0.170 |
Why?
| | Mannose-Binding Lectin | 1 | 2019 | 21 | 0.170 |
Why?
| | Medical Records | 1 | 2020 | 157 | 0.170 |
Why?
| | Nervous System Diseases | 1 | 2022 | 253 | 0.160 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2020 | 81 | 0.160 |
Why?
| | Medicine | 1 | 2020 | 103 | 0.160 |
Why?
| | Cardiac Surgical Procedures | 1 | 2023 | 433 | 0.160 |
Why?
| | Pulmonary Circulation | 2 | 2015 | 408 | 0.160 |
Why?
| | Reproducibility of Results | 4 | 2020 | 2814 | 0.160 |
Why?
| | CRISPR-Cas Systems | 1 | 2019 | 83 | 0.160 |
Why?
| | Cardiotonic Agents | 1 | 2019 | 119 | 0.160 |
Why?
| | Adult | 10 | 2024 | 30813 | 0.160 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 127 | 0.160 |
Why?
| | Drug Resistance, Bacterial | 1 | 2019 | 156 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2209 | 0.150 |
Why?
| | Blood Pressure | 4 | 2023 | 1536 | 0.150 |
Why?
| | Diabetes, Gestational | 1 | 2022 | 274 | 0.150 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 25 | 0.150 |
Why?
| | Hospitalization | 4 | 2023 | 1761 | 0.150 |
Why?
| | Academic Medical Centers | 2 | 2017 | 415 | 0.150 |
Why?
| | Calorimetry, Indirect | 1 | 2017 | 64 | 0.150 |
Why?
| | Proteomics | 3 | 2020 | 854 | 0.150 |
Why?
| | Renal Replacement Therapy | 1 | 2018 | 68 | 0.150 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 34 | 0.150 |
Why?
| | Chorioamnionitis | 1 | 2017 | 36 | 0.150 |
Why?
| | Medical Staff, Hospital | 1 | 2018 | 75 | 0.150 |
Why?
| | Motivation | 1 | 2021 | 496 | 0.150 |
Why?
| | Respiratory System | 1 | 2018 | 141 | 0.150 |
Why?
| | Toll-Like Receptor 4 | 1 | 2020 | 288 | 0.150 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 65 | 0.150 |
Why?
| | Cardiopulmonary Bypass | 1 | 2018 | 177 | 0.150 |
Why?
| | Mutation, Missense | 1 | 2019 | 296 | 0.150 |
Why?
| | Inservice Training | 1 | 2018 | 107 | 0.140 |
Why?
| | Heart Failure | 2 | 2021 | 1959 | 0.140 |
Why?
| | Delirium | 1 | 2018 | 66 | 0.140 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 477 | 0.140 |
Why?
| | Dysbiosis | 1 | 2018 | 145 | 0.140 |
Why?
| | Chronic Disease | 3 | 2022 | 1602 | 0.140 |
Why?
| | Pneumonia | 1 | 2022 | 576 | 0.140 |
Why?
| | Hemodynamics | 3 | 2023 | 970 | 0.140 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 179 | 0.140 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 416 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 445 | 0.140 |
Why?
| | Observer Variation | 1 | 2017 | 299 | 0.140 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 125 | 0.140 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 102 | 0.140 |
Why?
| | MicroRNAs | 1 | 2022 | 610 | 0.130 |
Why?
| | Fibroblasts | 1 | 2020 | 838 | 0.130 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 18 | 0.130 |
Why?
| | Mothers | 2 | 2022 | 667 | 0.130 |
Why?
| | Needs Assessment | 1 | 2017 | 320 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2019 | 295 | 0.130 |
Why?
| | Delphi Technique | 3 | 2020 | 164 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2020 | 2598 | 0.130 |
Why?
| | Computational Biology | 1 | 2019 | 528 | 0.130 |
Why?
| | Pre-Eclampsia | 1 | 2017 | 165 | 0.130 |
Why?
| | Organ Dysfunction Scores | 3 | 2020 | 39 | 0.130 |
Why?
| | Indiana | 1 | 2015 | 27 | 0.120 |
Why?
| | Medical Informatics | 1 | 2016 | 94 | 0.120 |
Why?
| | Hypokalemia | 1 | 2014 | 25 | 0.120 |
Why?
| | Trauma Centers | 3 | 2022 | 330 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2019 | 343 | 0.120 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 365 | 0.120 |
Why?
| | Bronchiolitis, Viral | 1 | 2013 | 10 | 0.120 |
Why?
| | Hypertension | 2 | 2019 | 1063 | 0.120 |
Why?
| | Hospitals, Pediatric | 3 | 2023 | 478 | 0.120 |
Why?
| | Birth Weight | 1 | 2017 | 439 | 0.120 |
Why?
| | Metabolomics | 1 | 2018 | 535 | 0.120 |
Why?
| | Schools, Medical | 1 | 2015 | 125 | 0.110 |
Why?
| | Signal Transduction | 2 | 2020 | 4525 | 0.110 |
Why?
| | Patient Care Team | 1 | 2018 | 521 | 0.110 |
Why?
| | Smoking | 2 | 2018 | 1468 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 751 | 0.110 |
Why?
| | Risk Assessment | 5 | 2018 | 3004 | 0.110 |
Why?
| | Colorado | 4 | 2017 | 4122 | 0.110 |
Why?
| | Physicians | 1 | 2021 | 774 | 0.110 |
Why?
| | Nasopharynx | 2 | 2023 | 63 | 0.110 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 42 | 0.110 |
Why?
| | Prognosis | 4 | 2023 | 3342 | 0.100 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 159 | 0.100 |
Why?
| | Incidence | 2 | 2018 | 2333 | 0.100 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2012 | 82 | 0.100 |
Why?
| | Risk | 2 | 2012 | 830 | 0.100 |
Why?
| | Carbon Dioxide | 2 | 2023 | 210 | 0.100 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 682 | 0.100 |
Why?
| | Antiphospholipid Syndrome | 1 | 2012 | 26 | 0.100 |
Why?
| | Precision Medicine | 1 | 2016 | 356 | 0.100 |
Why?
| | Polysaccharides | 1 | 2012 | 79 | 0.100 |
Why?
| | Abbreviated Injury Scale | 2 | 2021 | 21 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 448 | 0.100 |
Why?
| | Enoxaparin | 1 | 2012 | 52 | 0.100 |
Why?
| | Suction | 1 | 2011 | 31 | 0.100 |
Why?
| | Bacterial Load | 1 | 2011 | 60 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1008 | 0.100 |
Why?
| | Immunomodulation | 1 | 2012 | 86 | 0.100 |
Why?
| | Grief | 2 | 2021 | 35 | 0.100 |
Why?
| | Fatal Outcome | 1 | 2012 | 286 | 0.100 |
Why?
| | Anticoagulants | 2 | 2012 | 545 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2017 | 1033 | 0.100 |
Why?
| | Pressure | 2 | 2023 | 218 | 0.100 |
Why?
| | RNA, Ribosomal | 1 | 2011 | 157 | 0.090 |
Why?
| | Ultrasonography | 1 | 2015 | 671 | 0.090 |
Why?
| | Interferons | 2 | 2022 | 152 | 0.090 |
Why?
| | Aged | 3 | 2024 | 19295 | 0.090 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 225 | 0.090 |
Why?
| | Metagenome | 1 | 2011 | 122 | 0.090 |
Why?
| | RNA, Bacterial | 1 | 2011 | 174 | 0.090 |
Why?
| | Survival Rate | 3 | 2019 | 1653 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 196 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 233 | 0.090 |
Why?
| | Fetal Blood | 1 | 2012 | 268 | 0.090 |
Why?
| | Vitamin D | 1 | 2013 | 341 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2408 | 0.090 |
Why?
| | Blood Glucose | 2 | 2019 | 1826 | 0.090 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 42 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1728 | 0.090 |
Why?
| | Antihypertensive Agents | 1 | 2013 | 430 | 0.090 |
Why?
| | Stakeholder Participation | 2 | 2020 | 73 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 724 | 0.080 |
Why?
| | Influenza Vaccines | 1 | 2014 | 498 | 0.080 |
Why?
| | Survivors | 2 | 2022 | 405 | 0.080 |
Why?
| | Potassium | 2 | 2022 | 128 | 0.080 |
Why?
| | Sildenafil Citrate | 1 | 2008 | 58 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 4670 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2018 | 2167 | 0.080 |
Why?
| | Pediatrics | 1 | 2016 | 986 | 0.080 |
Why?
| | Hypoxia | 2 | 2024 | 936 | 0.080 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2008 | 63 | 0.080 |
Why?
| | Stem Cells | 1 | 2012 | 543 | 0.070 |
Why?
| | Stroke Volume | 2 | 2021 | 508 | 0.070 |
Why?
| | Purines | 1 | 2008 | 159 | 0.070 |
Why?
| | Pulmonary Edema | 1 | 2008 | 116 | 0.070 |
Why?
| | Transcriptome | 2 | 2023 | 741 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 934 | 0.070 |
Why?
| | Survival Analysis | 2 | 2022 | 1221 | 0.070 |
Why?
| | Diseases in Twins | 1 | 2008 | 175 | 0.070 |
Why?
| | Gene Expression | 2 | 2022 | 1442 | 0.070 |
Why?
| | Clinical Competence | 2 | 2023 | 918 | 0.070 |
Why?
| | Phenotype | 2 | 2023 | 2858 | 0.070 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 174 | 0.060 |
Why?
| | Cell Division | 2 | 2004 | 760 | 0.060 |
Why?
| | Cytokines | 1 | 2012 | 1857 | 0.060 |
Why?
| | Stroke | 1 | 2012 | 1014 | 0.060 |
Why?
| | Culture Media, Serum-Free | 1 | 2004 | 42 | 0.060 |
Why?
| | Chromones | 1 | 2004 | 35 | 0.060 |
Why?
| | Diffuse Axonal Injury | 1 | 2023 | 5 | 0.060 |
Why?
| | Aorta | 2 | 2004 | 354 | 0.060 |
Why?
| | Cardiac Catheterization | 1 | 2008 | 535 | 0.060 |
Why?
| | Carotid Artery Injuries | 1 | 2004 | 43 | 0.060 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 66 | 0.060 |
Why?
| | Disaccharides | 1 | 2023 | 16 | 0.060 |
Why?
| | Syndecan-1 | 1 | 2023 | 28 | 0.060 |
Why?
| | Androstadienes | 1 | 2004 | 97 | 0.060 |
Why?
| | Oligonucleotides, Antisense | 1 | 2004 | 99 | 0.060 |
Why?
| | Corpus Callosum | 1 | 2023 | 57 | 0.060 |
Why?
| | Heparitin Sulfate | 1 | 2023 | 42 | 0.060 |
Why?
| | Glycocalyx | 1 | 2023 | 21 | 0.060 |
Why?
| | Water-Electrolyte Balance | 1 | 2023 | 26 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 33 | 0.060 |
Why?
| | Morpholines | 1 | 2004 | 100 | 0.060 |
Why?
| | Probability | 1 | 2004 | 297 | 0.060 |
Why?
| | Hyperoxia | 1 | 2004 | 97 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 160 | 0.050 |
Why?
| | Proteoglycans | 1 | 2023 | 108 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2004 | 141 | 0.050 |
Why?
| | Vascular Resistance | 1 | 2004 | 338 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 11 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 139 | 0.050 |
Why?
| | Chemotactic Factors | 1 | 2022 | 47 | 0.050 |
Why?
| | Sirolimus | 1 | 2004 | 192 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2022 | 2021 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 541 | 0.050 |
Why?
| | Sodium Bicarbonate | 1 | 2022 | 40 | 0.050 |
Why?
| | White Matter | 1 | 2023 | 104 | 0.050 |
Why?
| | RNA, Viral | 2 | 2017 | 561 | 0.050 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 254 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 50 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 332 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 399 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 400 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2004 | 2262 | 0.050 |
Why?
| | Norepinephrine | 1 | 2022 | 206 | 0.050 |
Why?
| | Neonatologists | 1 | 2021 | 3 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 389 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 361 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 1724 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2022 | 157 | 0.050 |
Why?
| | Patient Acuity | 1 | 2021 | 41 | 0.050 |
Why?
| | Influenza in Birds | 1 | 2020 | 3 | 0.050 |
Why?
| | Leukocyte Common Antigens | 1 | 2020 | 75 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 758 | 0.050 |
Why?
| | Stromal Cells | 1 | 2020 | 97 | 0.050 |
Why?
| | Blood Gas Analysis | 1 | 2020 | 69 | 0.050 |
Why?
| | Birds | 1 | 2020 | 76 | 0.040 |
Why?
| | Bicarbonates | 1 | 2020 | 42 | 0.040 |
Why?
| | Hematoma, Subdural | 1 | 2019 | 16 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 949 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2021 | 308 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2020 | 69 | 0.040 |
Why?
| | Phosphorylation | 1 | 2004 | 1560 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 237 | 0.040 |
Why?
| | Skull Fractures | 1 | 2019 | 28 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2021 | 460 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 41 | 0.040 |
Why?
| | Child Health | 1 | 2020 | 134 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 180 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 731 | 0.040 |
Why?
| | Cardiac Output | 1 | 2019 | 143 | 0.040 |
Why?
| | Intracranial Hemorrhages | 1 | 2019 | 76 | 0.040 |
Why?
| | Maternal Exposure | 2 | 2012 | 137 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 386 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 108 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 582 | 0.040 |
Why?
| | Complement Activation | 1 | 2021 | 343 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3056 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 510 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2020 | 187 | 0.040 |
Why?
| | American Heart Association | 1 | 2020 | 266 | 0.040 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 140 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 961 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2019 | 267 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2024 | 486 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2021 | 240 | 0.040 |
Why?
| | Seasons | 1 | 2020 | 458 | 0.040 |
Why?
| | Animals | 5 | 2020 | 32119 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5035 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 336 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2004 | 788 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 533 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 246 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1374 | 0.040 |
Why?
| | Mortality | 1 | 2020 | 293 | 0.040 |
Why?
| | Creatinine | 1 | 2019 | 431 | 0.040 |
Why?
| | Data Collection | 1 | 2020 | 636 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2017 | 72 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1547 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 249 | 0.040 |
Why?
| | Causality | 1 | 2017 | 106 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2020 | 438 | 0.040 |
Why?
| | Calcium | 1 | 2022 | 1102 | 0.040 |
Why?
| | Homozygote | 1 | 2017 | 186 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1358 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2019 | 750 | 0.030 |
Why?
| | Family | 1 | 2020 | 591 | 0.030 |
Why?
| | Social Class | 1 | 2018 | 213 | 0.030 |
Why?
| | Point-of-Care Systems | 1 | 2018 | 150 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2004 | 3916 | 0.030 |
Why?
| | Registries | 1 | 2023 | 1773 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 339 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 550 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 106 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 778 | 0.030 |
Why?
| | Communication | 1 | 2021 | 749 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 551 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1476 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2581 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1138 | 0.030 |
Why?
| | Body Weight | 1 | 2019 | 872 | 0.030 |
Why?
| | Proteins | 1 | 2000 | 922 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 648 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1333 | 0.030 |
Why?
| | Orthomyxoviridae | 1 | 2014 | 35 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1817 | 0.030 |
Why?
| | Child Health Services | 1 | 2016 | 180 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 1919 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1149 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2503 | 0.030 |
Why?
| | Depression | 1 | 2021 | 1147 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1215 | 0.030 |
Why?
| | Immune System | 1 | 2013 | 173 | 0.030 |
Why?
| | Algorithms | 1 | 2019 | 1493 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1647 | 0.020 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 159 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 296 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2013 | 460 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 554 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 503 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1058 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2424 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2012 | 694 | 0.020 |
Why?
| | Global Health | 1 | 2008 | 292 | 0.020 |
Why?
| | Mice | 1 | 2020 | 15072 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 27079 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2000 | 215 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2000 | 522 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3258 | 0.010 |
Why?
|
|
Mourani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|